Therapeutic drug monitoring of etoposide in a 14-day infusion for non-small-cell lung cancer

Japanese Journal of Cancer Research

Volumn 87, Issue 2, 1996, Pages 200-205

  Ando, Yuichi ^a,b   Minami, Hironobu ^a   Saka, Hideo ^a   Ando, Masahiko ^b   Sakai, Shuzo ^b   Shimokata, Kaoru ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

Author keywords

Drug monitoring; Etoposide; Low dose; Non small cell lung cancer; Pharmacokinetics

Indexed keywords

ANTIBIOTIC AGENT; COLONY STIMULATING FACTOR; ETOPOSIDE;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; HUMAN CELL; INFECTIOUS COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL;

EID: 0029935554     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1996.tb03159.x     Document Type: Article

References (27)

1. Fleming, R. A., Miller, A. A. and Stewart, C. F. Etoposide: an update. Clin. Pharm., 8, 274-293 (1989).
2. O'Dwyer, P. J., Leyland-Jones, B., Alonso, M. T., Marsoni, S. and Wittes, R. E. Etoposide (VP-16-213). Current status of an active anticancer drug. N. Engl. J. Med., 312, 692-700 (1985).
3. Radice, P. A., Bunn, P. A., Jr. and Ihde, D. C. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies. Cancer Treat. Rep., 63, 1231-1237 (1979).
4. Loike, J. D. and Horwitz, S. B. Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells. Biochemistry, 15, 5443-5448 (1976).
5. Long, B. H., Musial, S. T. and Brattain, M. G. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res., 45, 3106-3112 (1985).
6. Drewinko, B. and Barlogie, B. Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213. Cancer Treat. Rep., 60, 1295-1306 (1976).
7. Dombernowsky, P. and Nissen, N. I. Schedule dependency of the antileukemic activity of the podophyllotoxin derivative VP 16-213 (NSC-141540) in L1210 leukemia. Acta Pathol. Microbiol. Scand. [A], 81, 715-724 (1973).
8. Roed, H., Vindelov, L. L., Christensen, I. J., Spang Thomsen, M. and Hansen, H. H. The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung. Cancer Chemother. Pharmacol., 19, 16-20 (1987).
9. Wolff, S. N., Grosh, W. W., Prater, K. and Hande, K. R. In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy. Cancer Chemother. Pharmacol., 19, 246-249 (1987).
10. Abratt, R. P., Willcox, P. A., de Groot, M., Goodman, H. T., Jansen, E. R. and Mame Salton, D. G. Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung carcinoma. Eur. J. Cancer, 27, 28-30 (1991).
11. Cavalli, F., Sonntag, R. W., Jungi, F., Senn, H. J. and Brunner, K. W. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. Cancer Treat. Rep., 62, 473-475 (1978).
12. Slevin, M. L., Clark, P. I., Joel, S. P., Malik, S., Osborne, R. J., Gregory, W. M., Lowe, D. G., Reznek, R. H. and Wrigley, P. F. M. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J. Clin. Oncol., 7, 1333-1340 (1989).
13. Kunitoh, H. and Watanabe, K. Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer. J. Clin. Oncol., 12, 83-89 (1994).
14. Thompson, D. S., Hainsworth, J. D., Hande, K. R., Holzmer, M. C. and Greco, F. A. Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study. J. Clin. Oncol., 11, 1322-1328 (1993).
15. Minami, H., Shimokata, K., Saka, H., Saito, H., Ando, Y., Senda, K., Nomura, F. and Sakai, S. Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer. J. Clin. Oncol., 11, 1602-1608 (1993).
16. Clark, P. I., Slevin, M. L., Joel, S. P., Osborne, R. J., Talbot, D. I., Johnson, P. W. M., Reznek, R., Masud, T., Gregory, W. and Wrigley, P. F. M. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J. Clin. Oncol., 12, 1427-1435 (1994).
17. Greco, F. A. Chronic etoposide administration: overview of clinical experience. Cancer Treat. Rev., 19 (Suppl. c), 35-45 (1993).
18. Miller, A. A., Tolley, E. A., Niell, H. B., Griffin, J. P. and Mauer, A. M. Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer. J. Clin. Oncol., 11, 1179-1188 (1993).
19. Harvey, V. J., Slevin, M. L., Joel, S. P., Smythe, M. M., Johnston, A. and Wrigley, P. F. M. Variable bioavailability following repeated oral doses of etoposide. Eur. J. Cancer Clin. Oncol., 21, 1315-1319 (1985).
20. Slevin, M. L., Joel, S. P., Papamichael, D., Smith, I., Ellis, P., Nicolson, M., Woodhull, J. and Talbot, D. C. Therapeutic monitoring of infusional etoposide in previously untreated small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol., 13, 133 (1994).
21. Waits, T. M., Johnson, D. H., Hainsworth, J. D., Hande, K. R., Thomas, M. and Greco, F. A. Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial. J. Clin. Oncol., 10, 292-296 (1992).
22. "WHO Handbook for Reporting Results of Cancer Treatment," Offset publication 48 (1979). World Health Organization, Geneva.
23. Ratain, M. J., Schilsky, R. L., Choi, K. E., Guarnieri, C., Grimmer, D., Vogelzang, N. J., Senekjian, E. and Liebner, M. A. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin. Pharmacol. Ther., 45, 226-233 (1989).
24. Ratain, M. J., Mick, R., Schilsky, R. L., Vogelzang, N. J. and Berezin, F. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J. Clin. Oncol., 9, 1480-1486 (1991).
25. Yamaoka, K., Tanaka, H., Okumura, K., Yasuhara, M. and Hori, R. An analysis program MULTI (ELS) based on extended nonlinear least squares method for microcomputers. J. Pharmacobiodyn., 9, 161-173 (1986).
26. Lam, F. C., Hung, C. T. and Perrier, D. G. Estimation of variance for harmonic mean half-lives. J. Pharm. Sci., 74, 229-231 (1985).
27. Stewart, C. F., Arbuck, S. G., Fleming, R. A. and Evans, W. E. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J. Clin. Oncol., 8, 1874-1879 (1990).